{"entity":{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","aka":["Y-90 ibritumomab","Zevalin therapeutic regimen"],"tldr":"Zevalin is an antibody carrying a radioactive isotope that seeks out CD20 on lymphoma cells. It treats follicular lymphoma that has relapsed and is given as a one-off consolidation after chemotherapy.","summary":"Ibritumomab tiuxetan was the first radioimmunotherapy approved by the FDA, in February 2002, for relapsed or refractory low-grade, follicular or transformed B-cell non-Hodgkin lymphoma including rituximab-refractory disease (Study 106-06: response in a majority of 54 rituximab-refractory patients), and in 2009 for consolidation after first-line chemotherapy in follicular lymphoma with a response (FIT trial: prolonged progression-free survival). The EU authorised Zevalin in 2004. Despite efficacy and a single-day treatment, use collapsed because of logistics between nuclear medicine and haematology, prolonged cytopenias and competition from rituximab maintenance and later agents; tositumomab (Bexxar) was discontinued in 2014. Severe cytopenias and infusion reactions carry boxed warnings.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ibritumomab%20tiuxetan"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan"},{"label":"EPAR","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin"}],"tags":["nci-list"],"related":["rituximab"],"cancers":["follicular-lymphoma"],"sections":[],"technologies":["radioimmunotherapy","monoclonal-antibody"],"targets":["cd20"],"drugs":[],"companies":["acrotech-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct01827605","nct00582166","nct01497275"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Zevalin","modality":"Radioimmunotherapy (yttrium-90 labelled anti-CD20 antibody)","mechanism":"Murine anti-CD20 IgG1 (the parent of rituximab) chelated via tiuxetan to yttrium-90; beta emission delivers radiation to CD20-positive B cells and neighbouring tumour cells (crossfire), given after rituximab to clear circulating B cells.","approvals":[{"region":"US","year":2002,"indication":"Relapsed or refractory low-grade, follicular or transformed B-cell NHL including rituximab-refractory follicular lymphoma"},{"region":"US","year":2009,"indication":"Consolidation after first-line chemotherapy in previously untreated follicular NHL"},{"region":"EU","year":2004,"indication":"Rituximab-relapsed or refractory CD20-positive follicular lymphoma; first-line consolidation added 2008"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[{"date":"2002-02-19","type":"accelerated-approval","region":"US","note":"Accelerated approval on a surrogate endpoint, with a confirmatory trial required.","indication":"Relapsed or refractory low-grade follicular or transformed B-cell NHL other than rituximab-refractory follicular NHL"},{"date":"2009-09-03","type":"conversion","region":"US","note":"Confirmed: the accelerated approval of 2002 converted to traditional approval 7.5 years after it was granted.","indication":"Relapsed or refractory low-grade follicular or transformed B-cell NHL other than rituximab-refractory follicular NHL"}]},"route":"/drugs/ibritumomab-tiuxetan/","neighbours":{"drug":[{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/"}],"trial":[{"id":"nct01827605","kind":"trial","name":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","route":"/trials/nct01827605/"},{"id":"nct00582166","kind":"trial","name":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","route":"/trials/nct00582166/"},{"id":"nct01497275","kind":"trial","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct01497275/"}]}}